Chronic Obstructive Pulmonary Disease (COPD): Pathophysiology, Clinical Manifestations, and Management

Chronic Obstructive Pulmonary Disease (COPD)

Overview

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, chronic, and irreversible disorder characterized by airflow obstruction due to airway inflammation, mucus production, and structural changes in the lungs. It encompasses two main conditions: chronic bronchitis and emphysema, often coexisting in patients.

• Chronic, recurrent disease

• Irreversible airflow obstruction

• Key features: airway inflammation, mucus production, fibrosis, loss of elastin, and alveolar destruction

COPD Etiology

Main Causes

The etiology of COPD is multifactorial, with environmental and genetic factors contributing to disease development.

• Inhalation of bronchial irritants:

  • Cigarette smoking (accounts for 80-85% of cases)

  • Industrial fumes, dust, particulates

  • Progression depends on exposure and genetic profile

  • Less than 50% of heavy smokers develop COPD

  • Lung function deterioration typically appears after 20-40 pack years

  • Most cases manifest in the 5th-6th decades of life

• α1-antitrypsin deficiency:

  • Uncommon, but important genetic risk factor

  • Early onset of disease

  • α1-antitrypsin is a major anti-protease protecting lung tissue from protease-mediated damage

COPD Pathogenesis

Inflammatory Mediators and Cellular Mechanisms

COPD pathology results from a complex interplay between noxious particles/gases and the lung's inflammatory response.

• Noxious particles/gases (e.g., cigarette smoke) trigger lung inflammation

• Key mediators: oxidative stress, proteases (e.g., neutrophil elastase), antiproteinases (e.g., α1-antitrypsin), and repair mechanisms

• Imbalance between proteases and antiproteases leads to tissue destruction

• Smoking inhibits macrophage apoptosis, limiting repair and promoting inflammation

COPD Types

Classification

COPD is classified into two main types, with most patients exhibiting features of both:

• Chronic bronchitis

• Emphysema

• Chronic bronchitis + Emphysema (most patients)

All types involve progressive inflammatory disease of the airways, alveoli, and pulmonary vasculature, resulting in irreversible airflow obstruction.

Pathophysiology: Chronic Bronchitis

Large Airways (Trachea/Bronchi)

• Mucus gland enlargement → increased sputum production

• Mucociliary clearance impaired (loss of cilia/cilia dysfunction)

• Airway inflammation mediated by neutrophils and macrophages

• Remodeling of airway walls (especially small airways):

  • Smooth muscle cell and connective tissue thickening

  • Fibrosis

• Decreased patency of bronchial airways (40% in mild/moderate, 80% in severe disease)

Small Airways (Small Bronchi/Bronchioles)

• Goblet cell metaplasia (replaces surfactant-producing cells)

Immune Dysregulation & Airway Obstruction

• IgA deficiency promotes bacterial invasion

• Macrophages have defective phagocytosis, promoting inflammation and protease production

• Inflammation and structural narrowing of airway:

  • Mucus plugging

  • Airway inflammation and edema

  • Fibrotic changes

• Results in decreased FEV1 (forced expiratory volume in 1 second)

Pathophysiology: Emphysema

Alveolar and Parenchymal Changes

• Elastin destruction and dysfunctional repair → loss of gas-exchanging airspaces (bronchioles, alveolar ducts, alveoli)

• Protease activity (e.g., neutrophil elastase) exceeds antiprotease protection (e.g., α1-antitrypsin)

• Enlarged alveolar airspace (loss of air exchange surface area)

• Decreased lung elasticity/recoil

• Prone to alveolar collapse due to loss of support structure and surfactant fluid

Types of Emphysema

• Centriacinar (centrilobular) emphysema: affects respiratory bronchioles, often associated with smoking

• Panacinar emphysema: affects entire acinus, associated with α1-antitrypsin deficiency

Pathophysiology: Progressive Hyperinflation

Progressive hyperinflation occurs due to air trapping in collapsed alveoli, leading to increased residual volume and total lung capacity.

• Loss of elastin and decreased surfactant

• Flattened diaphragm → less effective inspiration, early fatigue

• Expanded rib cage limits expansion-induced inspiration

Pathophysiology: Gas Exchange Impairment

Gas exchange impairment in COPD is due to non-uniform ventilation and destruction of pulmonary microvasculature, resulting in ventilation/perfusion (V/Q) mismatch.

• Non-uniform ventilation

• Pulmonary microvasculature destruction

• V/Q mismatch (see below for details)

• PaO2 normal until FEV1 is 50% of predicted

• PaCO2 normal until FEV1 is 25% of predicted

V/Q Mismatch Table

Condition	V/Q Ratio	Pathophysiology	Result
Normal	~0.8	Balanced ventilation and perfusion	Normal oxygenation
Low V/Q (Bronchitis)	<0.8	Impaired ventilation, normal perfusion	Hypoxemia
High V/Q (Emphysema)	>0.8	Impaired perfusion, normal ventilation	Hypoxemia
Shunt (very low V/Q)	0	No ventilation, normal perfusion	Severe hypoxemia

Pathophysiology: Pulmonary Circulation

• Pulmonary hypertension due to:

  • Emphysema-related destruction of alveolar-capillary interface

  • Hypoxia-induced pulmonary artery vasoconstriction

• Severe COPD can result in right-sided heart failure (cor pulmonale) due to pulmonary artery vasoconstriction

Clinical Manifestations

Respiratory Symptoms

• Dyspnea (chest heaviness, air hunger, gasping)

• Related to bronchitis:

  • Increased sputum production

  • Chronic cough (productive/unproductive)

• Related to obstruction:

  • Expiratory wheezing

  • Decreased FEV1, FEV1/FVC ratio

  • Pursed-lip breathing

  • Use of accessory respiratory muscles

• Related to alveolar destruction:

  • Arterial blood gases (late manifestation):

    • PaO2 < 80 mmHg (hypoxemia)

    • PaCO2 > 45 mmHg (hypercapnia)

  • Respiratory acidosis with compensatory metabolic alkalosis

  • Polycythemia due to chronic hypoxia

  • Lung hyperinflation

  • Barrel chest (increased anterior-posterior diameter)

Other Manifestations

• Fatigue/exercise intolerance

• Pulmonary arterial hypertension

• Right-sided heart failure

• Late stages: recurrent respiratory infections (exacerbations), respiratory failure

COPD Medications and Management

Pharmacological Therapy

• Smoking cessation (most important intervention)

• β2 agonists (bronchodilation)

  • Short acting: albuterol, levalbuterol

  • Long acting: salmeterol, formoterol

• Anticholinergics (reverse cholinergic-induced bronchoconstriction)

  • Short acting: ipratropium

  • Long acting: tiotropium

• Inhaled corticosteroids (less beneficial compared to asthma)

• O2 therapy for PaO2 < 55 mmHg

Key Terms and Definitions

• FEV1: Forced Expiratory Volume in 1 second; a measure of airway obstruction

• FVC: Forced Vital Capacity; total volume of air exhaled during a forced breath

• V/Q ratio: Ventilation/Perfusion ratio; balance between air reaching alveoli and blood perfusing alveoli

• PaO2: Partial pressure of oxygen in arterial blood

• PaCO2: Partial pressure of carbon dioxide in arterial blood

• Cor pulmonale: Right-sided heart failure due to pulmonary hypertension

Relevant Equations

• FEV1/FVC Ratio: $\text{FEV}_1/\text{FVC}$ Normal: > 0.7; COPD: < 0.7

• V/Q Ratio: $\text{V}/\text{Q}$ Normal: ~0.8

Summary Table: COPD Features

Feature	Chronic Bronchitis	Emphysema
Main Pathology	Airway inflammation, mucus production	Alveolar destruction, loss of elastin
Clinical Signs	Productive cough, wheezing	Dyspnea, barrel chest
V/Q Mismatch	Low V/Q	High V/Q
Key Risk Factor	Smoking	Smoking, α1-antitrypsin deficiency

Additional info: These notes expand on the original slides by providing definitions, clinical context, and structured tables for comparison and classification, as well as relevant equations for exam preparation.